Latest news with #VeevaSystems
Associated Press
a day ago
- Business
- Associated Press
Veeva to Present at Upcoming Investor Conferences
PLEASANTON, Calif., May 30, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced participation in the following investor conferences: The above presentations will be webcast. Links to the live and archived webcast will be available on Veeva's investor relations website at About Veeva Systems Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit Veeva uses its website as a means of disclosing material non-public information, announcing upcoming investor conferences, and for complying with its disclosure obligations under Regulation FD. Accordingly, you should monitor Veeva's investor relations website in addition to following its press releases, SEC filings, and public conference calls and webcasts. Investor Relations Contact: Gunnar Hansen Veeva Systems Inc. 267-460-5839 [email protected] Media Contact: Maria Scurry Veeva Systems Inc. 781-366-7617 [email protected] | View original content: SOURCE Veeva Systems
Yahoo
a day ago
- Business
- Yahoo
Veeva to Present at Upcoming Investor Conferences
PLEASANTON, Calif., May 30, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced participation in the following investor conferences: Baird 2025 Global Consumer, Technology & Services Conference, New York, NY. Paul Shawah, EVP Strategy, is presenting on Tuesday, June 3, 2025, at 10:50 a.m. Eastern Time. William Blair 45th Annual Growth Stock Conference, Chicago, IL. Brian Van Wagener, CFO, is presenting on Wednesday, June 4, 2025, at 1:20 p.m. Central Time. The above presentations will be webcast. Links to the live and archived webcast will be available on Veeva's investor relations website at About Veeva SystemsVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit Veeva uses its website as a means of disclosing material non-public information, announcing upcoming investor conferences, and for complying with its disclosure obligations under Regulation FD. Accordingly, you should monitor Veeva's investor relations website in addition to following its press releases, SEC filings, and public conference calls and webcasts. Investor Relations Contact: Gunnar HansenVeeva Systems Inc.267-460-5839ir@ Media Contact:Maria ScurryVeeva Systems Inc.781-366-7617pr@ View original content: SOURCE Veeva Systems
Yahoo
2 days ago
- Business
- Yahoo
VEEV Stock Up as Q1 Earnings & Revenues Beat Estimates, Margin Rise
Veeva Systems, Inc. VEEV reported adjusted earnings per share (EPS) of $1.97 for the first quarter of fiscal 2026, which increased 31.3% from the year-ago figure of $1.50. Adjusted EPS surpassed the Zacks Consensus Estimate by 13.22%. (Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.) GAAP EPS in the fiscal first quarter was $1.37, up 39.8% from the year-ago period's 98 cents. In the quarter under review, the company's revenues totaled $759 million, outpacing the Zacks Consensus Estimate by 4.3%. On a year-over-year basis, the top line improved 17%. The fiscal first-quarter top line was driven by Veeva Systems' robust segmental performance. Veeva Systems derives revenues from two operating segments — Subscription services and Professional services and other. In the fiscal first quarter, Subscription services revenues improved 18.9% from the year-ago quarter to $634.8 million. Per management, this uptick was driven by both its established and newer solutions. Our projection for fiscal first-quarter revenues was $595.8 million. Professional services and other revenues were up 6.8% year over year to $124.3 million. Our projection for fiscal first-quarter revenues was $102.3 million. In the quarter under review, Veeva Systems' gross profit improved 18.2% year over year to $585.2 million. The gross margin expanded 380 basis points (bps) to 77.1%. We had projected 72.4% of gross margin for the fiscal first quarter. Sales and marketing expenses increased 1.4% year over year to $98.6 million. Research and development (R&D) expenses rose 13.1% year over year to $184 million, while general and administrative expenses increased 12.3% year over year to $68.8 million. Total operating expenses of $351.5 million increased 9.4% year over year. Operating profit totaled $233.7 million, which increased 50.6% from the prior-year quarter. The operating margin in the fiscal first quarter expanded by a huge 690 bps to 30.8%. We had projected a 22.8% operating margin for the fiscal first quarter. Veeva Systems Inc. price-consensus-eps-surprise-chart | Veeva Systems Inc. Quote The company exited first-quarter fiscal 2026 with cash and cash equivalents and short-term investments of $6.07 billion compared with $5.15 billion at the fiscal 2025-end. Net cash provided by operating activities at the end of the quarter was $877.2 million compared with $763.5 million a year ago. Veeva Systems has issued its updated financial outlook for fiscal 2026 and provided its estimates for the second quarter of fiscal 2026. For the fiscal second quarter, the company expects total revenues between $766 million and $769 million. The Zacks Consensus Estimate is currently pegged at $754.5 million. Subscription revenues and Professional services and other revenues are estimated to be approximately $649 million and $117 million-$120 million, respectively, for the fiscal second quarter. For the fiscal second quarter, adjusted EPS is projected to be in the range of $1.89-$1.90. The Zacks Consensus Estimate is pegged at $1.79. Veeva Systems now expects revenues for fiscal 2026 between $3,090 million and $3,100 million compared with the previous guidance of $3,040 million and $3,055 million. The Zacks Consensus Estimate is currently pegged at $3.05 billion. For fiscal 2026, Subscription revenues are now expected to be approximately $2,625 compared with the previous guidance of $2,585 million. This consists of Commercial Solutions' subscription revenues of around $1,225 million and R&D Solutions' subscription revenues of approximately $1,400 million. Professional services and other revenues for fiscal 2026 are now expected to be between $465 million and $475 million. Adjusted EPS for fiscal 2026 is now expected to be $7.63 compared with the previous guidance of $7.32. The Zacks Consensus Estimate is pegged at $7.30. Veeva Systems exited the first quarter of fiscal 2026 with better-than-expected results, wherein both earnings and revenues beat their respective consensus estimate. The uptick in the overall top line and bottom line and robust performance by the Subscription services segment during the quarter were impressive. The uptick in Professional services and others' revenues also bodes well. Shares of the company gained 16.4% during after-market trading yesterday. The stock gained 11.5% in the year-to-date period compared with the industryand the S&P 500's growth of 13.8% and 0.2%, respectively. Per management, during the first quarter of fiscal 2026, Veeva Systems achieved a major milestone by surpassing its 2025 revenue run rate goal of $3 billion. This achievement highlights strong execution and continued momentum across both its Commercial and R&D Solutions. With a solid foundation now in place, Veeva Systems is well-positioned to make progress toward its long-term 2030 objective of doubling revenue while deepening its positive impact across the life sciences industry. Veeva Systems also announced a significant step forward in its artificial intelligence strategy with the introduction of Veeva AI. Set for an initial release in December 2025, Veeva AI will embed intelligent automation and productivity tools directly into its applications and Vault Platform. Features will include AI Agents and user-defined AI Shortcuts tailored to specific workflows in clinical and commercial functions. This initiative complements other key developments like the Veeva Direct Data API and the Veeva AI Partner Program, which are collectively aimed at transforming operational efficiency across life sciences. Further showcasing innovation, Veeva Systems hosted its Commercial Summit in May, where it highlighted upcoming AI capabilities such as CRM Bot, Voice Control, Compliant Free Text, and MLR Bot—tools expected to significantly boost productivity in commercial operations. The company also expanded its connected commercial data offerings with the launch of Veeva CRM Pulse, enhancing the Veeva Data Cloud with segmentation and targeting insights. With over 80 Vault CRM customers currently live and expectations to reach 200 next year, including three top 20 biopharmas, Veeva Systems continues to strengthen its position as a leader in connected software and data solutions. Image Source: Zacks Investment Research VEEV carries a Zacks Rank #3 (Hold) at present. Some better-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation CVS, Integer Holdings Corporation ITGR and AngioDynamics ANGO. CVS Health, carrying a Zacks Rank of 2 (Buy), reported first-quarter 2025 adjusted earnings per share (EPS) of $2.25, beating the Zacks Consensus Estimate by 31.6%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Revenues of $94.59 billion outpaced the consensus mark by 1.8%. CVS Health has a long-term estimated growth rate of 11.4%. Its earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%. Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank of 1. Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%. AngioDynamics, currently sporting a Zacks Rank #1, reported a third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a 13-cent loss. Revenues of $72 million beat the Zacks Consensus Estimate by 2%. ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 Composite's 10.5% growth. AngioDynamics' earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 70.9%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report Veeva Systems Inc. (VEEV) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
2 days ago
- Business
- Yahoo
Veeva Systems Delivers 'Solid' Fiscal Q1 Driven by Crossix Business, Oppenheimer Says
Veeva Systems (VEEV) delivered "solid" fiscal Q1 results driven by its Crossix data analytics platfo Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Business
- Yahoo
Reasons to Retain Veeva Systems Stock in Your Portfolio for Now
Veeva Systems Inc. VEEV is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid fourth-quarter fiscal 2025 performance and strategic deals, is expected to contribute further. However, rising operational costs remain a cause for concern. This Zacks Rank #3 (Hold) company's shares have risen 13.2% in the year-to-date period compared with 11.6% growth of the industry. The S&P 500 Composite has decreased 1.8% during the said time frame. The renowned provider of cloud-based software applications and data solutions for the life sciences industry has a market capitalization of $37.91 billion. The company anticipates 26.2% growth for the next five years and expects to maintain its strong performance in the future. It delivered a trailing four-quarter average earnings surprise of 7.92%. Image Source: Zacks Investment Research Robust Product Portfolio: Veeva Systems continues to drive the migration to its next-gen Vault CRM, with 20 new customers adopting the solution in the fourth quarter, particularly small and mid-sized biotech firms preparing for commercial launches. The company expects most top 20 pharma firms to make migration decisions by fiscal 2026, ahead of the 2030 sunset of the legacy CRM. Veeva Systems has introduced AI-driven innovations like CRM Voice Control, CRM Bot and MLR Bot to enhance efficiency, compliance and automation. Meanwhile, its Clinical Development Cloud sees growing adoption, with 17 of the top 20 pharma companies using its CTMS and a ninth committing to its EDC solution. Investments in RTSM and eCOA further expand its market opportunities. Veeva Systems' Data Cloud solutions—Compass, OpenData, Link, and the new Pulse—are gaining momentum. Compass supports over 100 brands, and Pulse secured its first seven-figure deal to enhance pharma segmentation and targeting. While enterprise-wide licensing is still in the early stages, larger contracts are expected. Veeva Systems is also expanding its Safety suite, offering a fully cloud-based solution for signal detection, adverse event reporting, and regulatory compliance, with automated updates and seamless clinical integration. Strategic Deals: Veeva Systems has secured several key deals in recent months, including Boehringer Ingelheim's commitment to migrate to Veeva Vault CRM, expanding its use of Veeva Commercial Cloud and Development Cloud. Additionally, ACTO joined the Veeva AI Partner Program to enhance generative AI capabilities for field representatives in life sciences. In October, Veeva Systems and Walgreens Boots Alliance announced a long-term partnership to leverage the former's Data Cloud and Clinical Platform, aiming to improve patient outcomes by connecting the latter's community locations with diverse patient populations for easier clinical research access. Strong Q4 Results: Veeva Systems exited the third quarter of fiscal 2025 with better-than-expected results, wherein both earnings and revenues beat their respective Zacks Consensus Estimate. This uptick in both top and bottom lines and robust performance by the Subscription services segment during the quarter were impressive. The rise in Professional services and others revenues also bodes well. Per management, Veeva Systems had a strong finish to the year by strengthening its partnerships across all customer segments, from large biopharma companies to smaller biotech firms. Rising Costs: Veeva Systems has been experiencing rising operating costs over the past few months. General and administrative expenses for the fourth quarter of fiscal 2025 increased 20.6% year over year. Management expects sales and marketing expenses to increase in fiscal 2025, primarily due to employee-related expenses as the company raises its headcount to support sales and marketing efforts associated with product offerings and the continued expansion of sales capacity across all solutions. In the fiscal fourth quarter, the total operating expenses increased 9.3% year over year. Veeva Systems expects operating expenses to increase in fiscal 2025, primarily due to employee compensation-related costs. Veeva Systems is witnessing a positive estimate revision trend for fiscal 2026. In the past 60 days, the Zacks Consensus Estimate for fiscal 2026 earnings per share (EPS) has moved a cent north to $7.30. The Zacks Consensus Estimate for first-quarter fiscal 2026 revenues is pegged at $727.9 million, indicating an 11.9% improvement from the year-ago quarter's reported number. The EPS estimate for the first quarter of fiscal 2026 is pinned at $1.74, implying a 16% improvement year over year. Some better-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation CVS, Integer Holdings Corporation ITGR and AngioDynamics ANGO. CVS Health, carrying a Zacks Rank of 2 (Buy), reported first-quarter 2025 adjusted earnings per share (EPS) of $2.25, beating the Zacks Consensus Estimate by 31.6%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Revenues of $94.59 billion outpaced the consensus mark by 1.8%. CVS Health has a long-term estimated growth rate of 11.4%. Its earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%. Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank of 1. Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%. AngioDynamics, currently sporting a Zacks Rank #1, reported a third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a 13-cent loss. Revenues of $72 million beat the Zacks Consensus Estimate by 2%. ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 Composite's 10.5% growth. AngioDynamics' earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 70.9%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report Veeva Systems Inc. (VEEV) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
